Who are 177Lu-RAD204's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Detectnet, somatostatin or terlipressin, Inj. Octreotide, combination with somatostatin analogue octreotide, Octreotide (drug), LAR Lanreotide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/177lu-rad204.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

177Lu-RAD204 — Competitive Intelligence Brief

177Lu-RAD204 (177Lu-RAD204) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Somatostatin receptor-targeting radioligand therapy. Area: Oncology.

phase 1 Somatostatin receptor-targeting radioligand therapy Somatostatin receptors Oncology Small molecule Live · refreshed every 30 min

Target snapshot

177Lu-RAD204 (177Lu-RAD204) — Radiopharm Theranostics, Ltd. Alpha-particle emitting radioligand targeting somatostatin receptors

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
177Lu-RAD204 TARGET	177Lu-RAD204	Radiopharm Theranostics, Ltd	phase 1	Somatostatin receptor-targeting radioligand therapy	Somatostatin receptors
Detectnet	copper dotatate Cu-64	Radiomedix	marketed	Radioactive Diagnostic Agent [EPC]	somatostatin receptors, particularly SSTR2	2020-01-01
somatostatin or terlipressin	somatostatin or terlipressin	National Science and Technology Council, Taiwan	marketed	Vasoactive peptide	Somatostatin receptors (SSTR) / Vasopressin V1 receptor
Inj. Octreotide	Inj. Octreotide	PVS Memorial Hospital	marketed	Somatostatin analog	Somatostatin receptors (SSTR2, SSTR5)
combination with somatostatin analogue octreotide	combination with somatostatin analogue octreotide	Ludwig-Maximilians - University of Munich	marketed	Somatostatin analogue	Somatostatin receptors (SSTR2, SSTR5)
Octreotide (drug)	Octreotide (drug)	Lahore General Hospital	marketed	Somatostatin analog	Somatostatin receptors (SSTR2, SSTR5)
LAR Lanreotide	LAR Lanreotide	Memorial Sloan Kettering Cancer Center	marketed	Somatostatin analog	Somatostatin receptors (SSTR2, SSTR5)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2032-08-23 — Detectnet · 10383961 · US
2032-08-23 — Detectnet · 10159759 · US
2032-08-23 — Detectnet · 11160888 · US

Sponsor landscape (Somatostatin receptor-targeting radioligand therapy class)

Radiopharm Theranostics, Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). 177Lu-RAD204 — Competitive Intelligence Brief. https://druglandscape.com/ci/177lu-rad204. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab